督保盟發言人滕西華痛批，食藥署作法形同「健保出錢讓全民當白老鼠，替廠商換取免做ＢＥ的門票」，她要求食藥署將違法藥品依法下架、通告違法藥品清單，並讓違法失職人員接受調查。.....???--滕西華是個公衛學者(?),似乎學名藥(Brand-Name)與商品藥(公羊藥?--Generic drugs)的現在的認知並不清楚!!......
美國因為歐巴馬要推動健保改革(Health Care Reforme),目前即將進入2014年(Insurance Exchange--最後健保改革是否成功的臨界點?),今年已經參院通過將Generic drugs納入Med-care與Venteran體系,;簡單說就是美國沒錢(財政懸岩?),又要增加健保照護面(預算增加?),;可能嗎????..... 不就是政策改變,;利益團體就要改變---經濟, 財政問題!!!
這期NEJM有三篇關於Generic drugs討論文章::
Coordination versus Competition in Health Care Reform
Katherine Baicker, Ph.D., and Helen Levy, Ph.D.
N Engl J Med 2013; 369:789-791August 29, 2013DOI: 10.1056/NEJMp1306268
Patenting the PKU Test — Federally Funded Research and Intellectual Property
Patents, Profits, and the American People — The Bayh–Dole Act of 1980
On Access and Accountability — Two Supreme Court Rulings on Generic Drugs
Marcia M. Boumil, J.D., LL.M., and Gregory D. Curfman, M.D.
N Engl J Med 2013; 369:696-697August 22, 2013DOI: 10.1056/NEJMp1308368
上期NEJM::---有關專利權,公平交易(?)等觀念---關係到教學醫院專利權轉移給Drugs Industry的利益分配問題?!!!
Taking Our Medicine — Improving Adherence in the Accountability Era
Lisa Rosenbaum, M.D., and William H. Shrank, M.D.
N Engl J Med 2013; 369:694-695August 22, 2013DOI: 10.1056/NEJMp1307084
The Unanticipated Consequences of Postponing the Employer Mandate
Mark V. Pauly, Ph.D., and Adam A. Leive, M.Sc.
N Engl J Med 2013; 369:691-693August 22, 2013DOI: 10.1056/NEJMp1308934
Gene Patenting — The Supreme Court Finally Speaks
Aaron S. Kesselheim, M.D., J.D., Robert M. Cook-Deegan, M.D., David E. Winickoff, J.D., and Michelle M. Mello, J.D., Ph.D.
N Engl J Med 2013; 369:869-875August 29, 2013DOI: 10.1056/NEJMhle1308199........
台灣cGMP藥廠>90%僅是商品藥製造代工而已,---原料來源::第一名是中國大陸,;第二名是印度....;騰女士的發言代表甚麼利益團體?!!!...立委(民進黨不分區)是可以發言的...因為關係利益團體的權益(又有政黨背書)!!!
Patents, Profits, and the American People — The Bayh–Dole Act of 1980
Howard Markel, M.D., Ph.D.
N Engl J Med 2013; 369:794-796August 29, 2013DOI: 10.1056/NEJMp1306553
In June, the U.S. Supreme Court issued a unanimous opinion in Association for Molecular Pathology v. Myriad Genetics that invalidated the claim of ownership of the BRCA1 and BRCA2 genes. On one level, the legal contretemps leading up to this decision grew out of the University and Small Business Patent Procedures Act of 1980, commonly known as the Bayh–Dole Act.1 Sponsored by Senators Birch Bayh (D-IN) and Robert Dole (R-KS), the law reversed decades of government policy by allowing scientists, universities, and small businesses to patent and profit from discoveries they made through federally funded research — like Myriad's research on breast-cancer genetics, which built on previous publicly funded work and was partially supported by the National Institutes of Health.
The Bayh–Dole Act is beloved by the biotechnology and investment communities. In 2002, the Economist經濟學人雜誌called it “possibly the most inspired piece of legislation to be enacted in America over the past half-century” because it “helped to reverse America's precipitous倉促的 急躁的 slide into industrial irrelevance不恰當 無關係 不對題.”2 The law certainly contributed substantially to the increase in patents awarded to universities over the past three decades — from 380 in 1980 to 3088 in 2009. More difficult to confirm is industry's estimate that between 1996 and 2007, university-based research-licensing agreements contributed $47 billion to $187 billion to the gross domestic product.3 Indeed, the law's many critics question how much it has actually benefited the economy (as opposed to individuals and shareholders) and the extent of its social costs.
我們台灣是台大,中研院,國衛院,甚至還未完成新藥的 phase III就發布新聞,轉移技術給"生技公司"生產 上市;;--牛樟菇就是好例子!!(還好是以健康食品販賣?!劑量更不知道!! 吃死人?! 怎辦?!只要政治正確--發展生技,ˊ政府與學界就會背書???),--公衛專家就是做這些事的(?).....
